PER 34.1% 8.9¢ percheron therapeutics limited

UPDATE ON PFIZER’S PHASE 1B OPEN-LABEL MINI-DYSTROPHIN GENE THERAPY TRIAL FOR DUCHENNE, page-22

  1. 13,599 Posts.
    lightbulb Created with Sketch. 1454
    https://www.health.gov.au/health-topics/chronic-conditions/what-were-doing-about-chronic-conditions/what-were-doing-about-rare-diseases

    Anp can apply for a research grant.Re Rare Diseases and Fibrosis
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.